46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100046283 | 2021-05-30 | 2021-05-12 | Study on the mechanism of pirfenidone in the treatment of connective tissue disease with interstitial lung disease | Study on the mechanism of pirfenidone in the treatment of connective tissue disease with interstitial lung disease | rheumatoid arthritis | Experimental group:pirfenidone; | The First Affiliated Hospital of DaLian Medical University | NULL | Pending | 18 | 70 | Both | Experimental group:100; | Phase 4 | China |
| 2 | EUCTR2017-000149-30-GB (EUCTR) | 25/10/2017 | 05/09/2017 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease - TRAIL1 | Rheumatoid arthritis associated interstitial lung disease (RA-ILD);Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Esbriet INN or Proposed INN: Pirfenidone | University Hospitals of Leicester NHS Trust | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 270 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Canada;Australia;United Kingdom | ||
| 3 | NCT02808871 (ClinicalTrials.gov) | April 7, 2017 | 20/3/2016 | Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1) | Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease (TRAIL1) | Rheumatoid Arthritis Interstitial Lung Disease | Drug: Pirfenidone;Drug: Placebo | Brigham and Women's Hospital | NULL | Completed | 18 Years | 85 Years | All | 123 | Phase 2 | United States;Australia;Canada;United Kingdom |